马拉维的PMRA对Bahir Dar大学88.4%的不合格药品索赔提出异议，并引用了4%的来自他们自己的数据。 Malawi's PMRA disputes Bahir Dar University's 88.4% substandard medicine claim, citing 4% from their own data.
马拉维药房和药品监管局（PMRA）对巴赫达尔大学（Bahir Dar University）的一项研究结果提出异议，该研究声称马拉维的不合格和假冒药品在非洲的流行率最高，为88.4%。 Malawi's Pharmacy and Medicines Regulatory Authority (PMRA) disputes findings from a Bahir Dar University study, which claimed that Malawi had the highest prevalence of substandard and falsified medicines in Africa at 88.4%. Mphatso Kawaye总干事引用了四年来例行质量监测活动的数据,表明流行率为4%。 PMRA Director General Mphatso Kawaye cited data from routine quality surveillance activities over four years indicating a prevalence rate of 4%. 马拉维政府强调需要进行准确的研究, 并向公众保证马拉维承诺确保药物的安全性,有效性和质量. PMRA emphasizes the need for accurate research and assures the public of Malawi's commitment to ensuring the safety, efficacy, and quality of medicines.